ScripWrapping up a challenging 2023, Chinese pharma firms increasingly ventured into the US to initiate Phase III clinical trials to support future regulatory approvals from the US Food and Drug Administra
ScripMega-sized financing deals backed by venture capital and private equity firms have bypassed Chinese biotechs, since a string of transactions worth $100m impressed the sector around the turn of the yea
ScripThree Chinese bioventures completed financing activities in the second half of July, raising roughly $175m combined. TransThera Biosciences Co. Ltd. raised roughly $100m in a Series D venture capita
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CANbridge Addresses China’s Rare Diseas